Home › Roche ALK Test Gains FDA Approval as CDx for Zykadia

Roche ALK Test Gains FDA Approval as CDx for Zykadia

Jun 01, 2017

NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved Roche's Ventana ALK (D5F3) CDx to identify best responders to Novartis' non-small cell lung cancer drug Zykadia (ceritinib).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

What's Popular?

In Molecular Diagnostics

  1. Guardant Health to Develop Blood-Based CDx for AstraZeneca Drugs

  2. Exosome Diagnostics Suing Former Employee for IP Theft

  3. Curetis to Cut 30 Percent of Workforce as Part of Strategic Restructuring

  4. Black Women With Breast Cancer Fare Worse, TAILORx Analysis Confirms at SABCS

    Premium

  5. Guardant Health to Launch Cell-Free DNA Assay for Cancer Recurrence Monitoring in 2019

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.